You have 9 free searches left this month | to do more

deferasirox

Deferasirox is a drug used to treat Iron Overload, Myelodysplastic Syndromes, Myelodysplastic Syndrome, and other conditions. Deferasirox is being actively studied in 2 studies and prior, has been studied in 39.

Top SponsorsTop SitesTop Investigators
Novartis PharmaceuticalsNovartis Investigative SiteAmit Pandya
NovartisChildren's Hospital BostonAntonello Di Paolo, M.D., Ph.D.
Boston Children's HospitalChildren's Hospital of PhiladelphiaDr Koren Ariel
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Completed
  • Beta-thalassemia
  • Iron Overload
  • Deferasirox
  • Los Angeles, California
  • +2 more
2021-06-08
Jun 8, 2021
U
Recruiting
  • Myelodysplasia
  • Deferasirox
  • Grenoble, France
    CHU de GRENOBLE ALPES
2021-10-01
Oct 1, 2021
N
Completed
  • β-thalassemia
  • Transfusional Iron Overload
  • Deferasirox
  • Cagliari, CA, Italy
  • +2 more
2020-12-06
Dec 6, 2020
N
Completed
  • Hepatic Impairment
  • Deferasirox
  • Kiel, Germany
    Novartis Investigative Site
2020-12-06
Dec 6, 2020
N
Completed
  • Myelodysplastic Syndromes
  • Iron Overload
  • Deferasirox
  • Stanford, California
  • +2 more
2021-06-01
Jun 1, 2021
U
Active, not recruiting
  • Iron Overload
  • Deferasirox
  • Trieste, Italy
    IRCCS Burlo Garofolo
2022-01-04
Jan 4, 2022
F
Terminated
  • Anemia
  • Myelodysplastic Syndrome
  • Deferasirox
  • Laboratory Biomarker Analysis
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2020-06-12
Jun 12, 2020
C
Completed
  • Chronic Iron Overload
  • Lushnjë, Albania
  • +21 more
2021-04-08
Apr 8, 2021
N
Terminated
  • Transfusion-dependent β-thalassemia Patients
  • Cardiac Iron Overload
  • Deferasirox
  • Deferoxamine (DFO)
  • Athens, GR, Greece
  • +3 more
2019-10-21
Oct 21, 2019
N
Completed
  • Chronic Iron Overload
  • Deferasirox
  • Vienna, Austria
  • +13 more
2020-02-18
Feb 18, 2020
S
Withdrawn
  • Transfusional Iron Overload
  • +6 more
  • (no location specified)
2021-06-01
Jun 1, 2021
B
Completed
  • Transfusion-dependent Hemachromatosis
  • +2 more
  • Boston, Massachusetts
    Children's Hospital Boston
2019-06-14
Jun 14, 2019
N
Completed
  • Non-transfusion Dependent Thalassemia
  • deferasirox
  • Nanning, Guangxi, China
  • +10 more
2019-09-19
Sep 19, 2019
N
Completed
  • Myelodysplastic Syndrome
  • Iron Overload
  • Deferasirox
  • Birmingham, Alabama
  • +47 more
2021-07-21
Jul 21, 2021
E
Terminated
  • Acute Myeloid Leukemia
  • Deferasirox
  • +2 more
  • Maywood, Illinois
    Loyola University Cardinal Bernardin Cancer Center
2020-02-25
Feb 25, 2020
F
Unknown status
  • Myelodysplastic Syndromes
  • Deferasirox
  • Firenze, FI, Italy
  • +9 more
2019-07-15
Jul 15, 2019
N
Terminated
  • Myelodysplastic Syndrome
  • Bone marrow aspirate
  • Deferasirox
  • Liege, Belgium
    Novartis Investigative Site
2018-07-24
Jul 24, 2018
N
Completed
  • Myelodysplastic Syndromes
  • Deferasirox
  • Placebo
  • Anaheim, California
  • +71 more
2020-10-30
Oct 30, 2020
N
Completed
  • Transfusion-dependent Iron Overload
  • Deferasirox
  • Adelaide, Australia
  • +97 more
2020-02-08
Feb 8, 2020
C
Terminated
  • Iron Overload
  • +101 more
  • deferasirox
  • Duarte, California
    City of Hope
2019-06-07
Jun 7, 2019
M
Terminated
  • Breast Cancer
  • +7 more
  • deferasirox
  • Minneapolis, Minnesota
    Masonic Cancer Center at University of Minnesota
2017-12-03
Dec 3, 2017
W
Completed
  • Acute Undifferentiated Leukemia
  • +135 more
  • deferasirox
  • +2 more
  • Winston-Salem, North Carolina
    Comprehensive Cancer Center of Wake Forest University
2018-08-07
Aug 7, 2018
N
Completed
  • Beta-thalassemia
  • +4 more
  • Deferasirox
  • Oakland, California
  • +5 more
2017-08-17
Aug 17, 2017
N
Withdrawn
  • Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD
  • Deferasirox
  • (no location specified)
2017-04-19
Apr 19, 2017